popular attention for its wide participation in various pathological process recently. In this paper, a series of novel derivatives containing 2, 5-diketopiperazine (DKP) skeleton were developed as potent selective HDAC6 inhibitors (sHDAC6is). Most of these compounds exhibited low nanomolar IC50 values toward HDAC6, and the best compound was 21b (IC50 = 0.73 nM) which had 144-10941-fold selectivity
组蛋白脱乙酰基酶6(H
DAC6)最近因广泛参与各种病理过程而受到广泛关注。在本文中,开发了一系列含有2,5-二酮
哌嗪(DKP)骨架的新型衍
生物作为有效的选择性H
DAC6
抑制剂(sH
DAC6is)。这些化合物大多数对H
DAC6表现出较低的纳摩尔IC50值,最佳化合物为21b(IC50 = 0.73 nM),其选择性是其他H
DAC同种型的144-10941倍。蛋白质印迹法进一步验证了这些化合物为sH
DAC6is。进行了21b的分子模拟,以合理化对H
DAC6的高结合亲和力。在细胞毒性实验中,与ACY-1215相比,18a,18b和18d对两个多发性骨髓瘤细胞U266和RPMI-8226的生长产生了优越或相当的影响。而且,18a和
阿霉素的组合显示出对非小细胞肺癌细胞A549的协同作用。图18a和18b还证明了人肝微粒体(HLM)中适当的药物代谢。